Vaccine developer Inventprise is cutting 76 workers across its Washington facilities, representing nearly 40% of its workforce. The layoffs come as the company advances its pneumococcal vaccine candidate through clinical trials.
Beyond Pandemic Protection: mRNA Vaccines’ Surprising Role in Cancer Care In a remarkable medical discovery, mRNA COVID-19 vaccines are demonstrating…
The New Era of Proactive Health Management In an age where customization dominates consumer experiences—from algorithm-driven entertainment to personalized shopping—healthcare…
The Temperature-Sensitive Innovation Scientists at the University of Surrey have developed a revolutionary color-changing label technology that promises to dramatically…
